Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Video: Jeanne Martel, ClinicalMind

Video: Jeanne Martel, ClinicalMind

Jeanne Martel, president and partner at ClinicalMind, highlights her company's vision and expertise in communication and technology with MM&M's Jaimy Lee.

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study

The organization said it used Facebook to identify participants for a study designed to identify biomarkers associated with Parkinson's disease.

Five things for pharma marketers to know: Tuesday, September 13, 2016

Five things for pharma marketers to know: Tuesday, September 13, 2016

Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

Event company acquires AstraZeneca's medical meetings app

Event company acquires AstraZeneca's medical meetings app

The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Five things for pharma marketers to know: Tuesday, July 19, 2016

Five things for pharma marketers to know: Tuesday, July 19, 2016

The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Five things for pharma marketers to know: Monday, June 13, 2016

Five things for pharma marketers to know: Monday, June 13, 2016

A new Sanofi combination diabetes drug meets clinical trial targets; IBM partners with the American Diabetes Association; Dr. Reddy's to buy eight Teva drugs

Pharma companies turn to wearables to improve R&D

Pharma companies turn to wearables to improve R&D

Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Five things for pharma marketers to know: Tuesday, April 19, 2016

Five things for pharma marketers to know: Tuesday, April 19, 2016

Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class

Infographic: Better promotion of clinical trials

Infographic: Better promotion of clinical trials

Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

Five things for pharma marketers to know: Friday, March 11, 2016

Five things for pharma marketers to know: Friday, March 11, 2016

Valeant CEO reportedly tells staffers that the worst is behind them; Sanofi hires chief medical officer from Novartis; PhRMA CEO says pricing debate is misinformed

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.

Sensors, technology open the door to new era for clinical trials

Sensors, technology open the door to new era for clinical trials

Welcome to the mobile era for clinical trials, in which phone and tablet technology promise to upend a costly and unwieldy process.

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Twitter, Facebook, Google execs examine regulatory limits for drugmakers

Twitter, Facebook, Google execs examine regulatory limits for drugmakers

Technology executives discussed how pharma companies can leverage social media to better engage with patients online.

How physician preference for mobile influences strategy

How physician preference for mobile influences strategy

Physicians like mobile and they prefer the iPhone to Android devices — and that knowledge is changing the way drugmakers promote their products online.

Five things for pharma marketers to know: Thursday, February 25, 2016

Five things for pharma marketers to know: Thursday, February 25, 2016

Senate approves Califf as FDA commissioner; one-fifth of published trial data is used for "marketing trials;" Valeant CEO Pearson is on the mend

Startup unveils tools to improve trial reproducibility

Startup unveils tools to improve trial reproducibility

The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.

Five things for pharma marketers to know: Wednesday, December 30, 2015

Five things for pharma marketers to know: Wednesday, December 30, 2015

Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles

Five things for pharma marketers to know: Tuesday, December 8, 2015

Five things for pharma marketers to know: Tuesday, December 8, 2015

Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma

AstraZeneca to use mobile app in cancer trials

AstraZeneca to use mobile app in cancer trials

AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

Five things for pharma marketers to know: Tuesday, November 3, 2015

Five things for pharma marketers to know: Tuesday, November 3, 2015

GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development

Five things for pharma marketers to know: Tuesday, October 20, 2015

Five things for pharma marketers to know: Tuesday, October 20, 2015

Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands

Five things for pharma marketers to know: Friday, October 16, 2015

Five things for pharma marketers to know: Friday, October 16, 2015

The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments

Five things for pharma marketers to know: Tuesday, October 13, 2015

Five things for pharma marketers to know: Tuesday, October 13, 2015

Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo

Five things for pharma marketers to know: Wednesday, October 7, 2015

Five things for pharma marketers to know: Wednesday, October 7, 2015

Califf reportedly removes name from research questioning FDA oversight of clinical trials; Express Scripts to cover both PCSK9 inhibitors; trial for experimental cancer drug halted after patient death

Mobile sensors and digital devices may cut costs at GSK

Mobile sensors and digital devices may cut costs at GSK

A GSK manager said that bringing digital devices to clinical trials could lower the cost of bringing medicines to patients.

Wearables Create a New World of Data for Clinical R&D

Wearables Create a New World of Data for Clinical R&D

By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.

Five things for pharma marketers to know: Monday, September 28, 2015

Five things for pharma marketers to know: Monday, September 28, 2015

PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval

New Turing CCO steps down amid drug price controversy

New Turing CCO steps down amid drug price controversy

Craig Rothenberg joined Turing as its first comms chief less than two months ago.

Today the clinical trial, tomorrow the world

Today the clinical trial, tomorrow the world

As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

Five things for pharma marketers to know: Wednesday, August 19

Five things for pharma marketers to know: Wednesday, August 19

Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations

Amgen settles off-label case with states

Amgen settles off-label case with states

State attorneys general accused the drugmaker of violating state consumer protection laws.

Five things for pharma marketers to know: Tuesday, August 18

Five things for pharma marketers to know: Tuesday, August 18

Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

Five things for pharma marketers to know: Friday, August 14

Five things for pharma marketers to know: Friday, August 14

GSK studying Breo Ellipta in lung-cancer patients; researchers develop strains of yeast for painkillers in a lab; Wolters Kluwer acquires CME provider

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.

We're searching for 2015's Outstanding Contributor to Healthcare

We're searching for 2015's Outstanding Contributor to Healthcare

Know a very special person or group making extraordinary contributions to public health? We want to hear from you.

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.

Everyday Health expects growth from consolidated offerings and specialty brands

Everyday Health expects growth from consolidated offerings and specialty brands

The media company said orphan drugs and specialty medicines, like PCSK9 inhibitors, will drive the company's business going forward.

Five things for pharma marketers to know: Wednesday, August 12

Five things for pharma marketers to know: Wednesday, August 12

J&J turns to digital marketing in China; GSK closes North Carolina facility; Kim Kardashian West's promotion of Diclegis increased online conversations about the brand

Everyday Health buys hospital marketing firm

Everyday Health buys hospital marketing firm

The company acquired Tea Leaves Health for $30 million to diversify its business.

Five things for pharma marketers to know: Tuesday, August 11

Five things for pharma marketers to know: Tuesday, August 11

"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling

How Direct Marketing Must Adapt in Today's Healthcare System

How Direct Marketing Must Adapt in Today's Healthcare System

By breaking down traditional organizational silos to bring together the chief medical officer and the chief marketing officer, companies can unite the forces of clinical best practices with direct-to-consumer response marketing.

Judge grants relief to Amarin in off-label case

Judge grants relief to Amarin in off-label case

The decision, a setback for the FDA, allows the drugmaker to move forward with plans to legally promote some off-label information.

The MM&M Weekly News Quiz: August 7

The MM&M Weekly News Quiz: August 7

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Allergan sales rise on "strong" DTC advertising

Allergan sales rise on "strong" DTC advertising

Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.

Five things for pharma marketers to know: Thursday, August 6

Five things for pharma marketers to know: Thursday, August 6

AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.

Astellas to use rugby to promote prostate-cancer awareness

The drugmaker, which sells prostate-cancer treatment Xtandi, wants social-media users to help spread the word about the disease

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Firms promising Rx savings deepen ties to EHR platforms

Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Healthcare reimagined: Fortner finesses McKesson's bold vision

Healthcare reimagined: Fortner finesses McKesson's bold vision

From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 31

Five things for pharma marketers to know: Friday, July 31

Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment

Wunderman Health acquires ABS Creative

The New York-based agency took a majority stake in the full-service healthcare agency.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

More patients are seeking treatments with even fewer side effects and shorter durations.

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Graphic: the new hepatitis-C drug market

Graphic: the new hepatitis-C drug market

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

OPINION

Email Newsletters